39082-07-0

Upstream product

• 22968-45-2 Selenophene-2-carboxylic acid 
• 25109-26-6 selenophene-2-carbaldehyde 
• 15429-03-5 2-acetylselenophene 

Downstream Products

• 55685-51-3 2-(N,N-Dimethylcarboxamido)-selenophen 
• 1032315-50-6 dibenzyl 2-(2'-selenophenyl)-6,7-methylenedioxyquinolin-4-yl-phosphate 
• 1350903-36-4 N-(2-acetyl-3,4-dimethoxyphenyl)selenophene-2-carboxamide 
• 1350903-37-5 N-(2-acetyl-4-methoxyphenyl)selenophene-2-carboxamide 
• 1346457-01-9 succinic acid mono-[5-(1-benzyl-selenolo[3,2-c]pyrazol-3-yl)furan-2-yl]methyl ester 
• 1346456-97-0 C₁₈H₁₆N₂O₃Se 
• 1346456-69-6 5-methoxycarbonyl-2-furyl 2-selenophenyl phenylhydrazone 
• 1223581-05-2 1-benzyl-3-(5-hydroxycarbonyl-2-furyl)selenolo[3,2-c]pyrazole 
• 1115951-96-6 1-benzyl-3-(5-hydroxymethyl-2-furyl)selenolo[3,2-c]pyrazole 
• 1223580-94-6 1-benzyl-3-(5-methoxycarbonyl-2-furyl)selenolo[3,2-c]pyrazole 
• 1223581-04-1 1-phenyl-3-(5-hydroxycarbonyl-2-furyl)selenolo[3,2-c]pyrazole 
• 1223580-99-1 1-phenyl-3-(5-hydroxymethyl-2-furyl)selenolo[3,2-c]pyrazole 
• 1223580-93-5 1-phenyl-3-(5-methoxycarbonyl-2-furyl)selenolo[3,2-c]pyrazole 

Relevant academic research and scientific papers

Selenolopyrazole derivatives and use thereof as anticancer agents

The present invention synthesizes a series of selenolo[3,2-c]pyrazole and selenolo[2,3-c]pyrazole derivatives, and discovers their anticancer activity.

Synthesis and in vitro anticancer activity of 6,7-methylenedioxy (or 5-hydroxy-6-methoxy)-2-(substituted selenophenyl)quinolin-4-one analogs

6,7-Methylenedioxy (or 5-hydroxy-6-methoxy)-2-(substituted selenophenyl)quinolin-4-ones and their isosteric compounds were synthesized and evaluated for anticancer activity. Structure-activity relationships (SAR) of these compounds were established. Among all tested compounds, 6,7-methylenedioxy-2-(5-methylselenophen-2-yl)quinolin-4-one (4d) was found to be the most promising anticancer agent. In screening against NCI's 60 human tumor cell line panel, 4d exhibited highly selective and potent inhibitory activity against MDA-MB-435 melanoma. Furthermore, the results of COMPARE analysis suggested that 4d is an antimitotic agent with a different mechanism of action from the conventional antimitotic agents, such as colchicine, vinca alkaloids and paclitaxel. Therefore, 4d was identified as a new lead compound that merits further optimization.

Synthesis of 1-benzyl-3-(5-hydroxymethyl-2-furyl)selenolo[3,2-c]pyrazole derivatives as new anticancer agents

As part of our continuing search for potential anticancer drug candidates among YC-1 analogs, 1, 3-disubstituted selenolo[3,2-c]pyrazole derivatives were synthesized and evaluated for their cytotoxicity against NCI-H226 non-small cell lung cancer and A-498 renal cancer cell lines. Significant cytotoxicity was observed in 3-(5-hydroxymethyl-2-furyl) derivatives (2, 33, 36 and 37). Among them, compound 2 was found to have the most potent activity. The mode of action of compound 2 seems to differ from those of the 175 anticancer agents listed in NCI's standard database and resembles that of YC-1. Thus, we recommend that compound 2 should be developed further as new drug candidate for treatment of non-small cell lung cancer and renal cancer.

NOVEL HYDROPHILIC DERIVATIVES OF 2-ARYL-4-QUINOLONES AS ANTICANCER AGENTS

2-aryl-4-quinolones are converted into phosphates by reacting with tetrabenzyl pyrophosphate to form dibenzyl phosphates thereof, which are then subject to hydrogenation to replace dibenzyl groups with H, followed by reacting with Amberlite IR-120(Na+ form) to form disodium salts. The results of preliminary screening revealed that these phosphates showed significant anti-cancer activity. A novel intermediate, 2-selenophene 4-quinolone and Λ/, Λ/-dialkylaminoalkyl derivatives of 2-phenyl-4-quinolones are also synthesized. These novel intermediates exhibited significant anticancer activities.